Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
There is a question that sits underneath almost every account of transformation, whether the language used is spiritual, therapeutic, or purely clinical: how does a single experience leave a mark that outlives itself?
People who have sat through one genuinely shattering night — a bereavement, a vision, a ceremony, a moment of grace on an ordinary Tuesday — often describe the same odd aftermath. Nothing about them looks different. The face in the mirror is the face from before. And yet something in the way they meet the world has quietly, permanently shifted. The experience ended. Its effect did not.
Neuroscience has been circling this question from the other direction, and a study published in Neuropsychopharmacology has just delivered an answer that is more interesting than the one most researchers expected.
The puzzle worth solving
Psilocybin has drawn intense scientific attention for one reason above all others: the durability of its effects. Standard antidepressants must be taken daily and often take weeks to do anything. Psilocybin, in trial settings, appears to do something different. When researchers followed up with cancer patients who had received a single dose alongside psychotherapy, reductions in anxiety, depression, hopelessness and demoralisation were still measurable years later — with most participants ranking the experience among the most personally meaningful of their lives.
That kind of persistence demands a mechanism. One dose, one afternoon, and then months or years of altered baseline. What could possibly hold that in place?
The field’s favourite answer has been structural plasticity — the idea that the brain physically rebuilds itself. There was good evidence for it. Yale researchers using two-photon microscopy found that a single dose of psilocybin increased the size and density of dendritic spines in the mouse frontal cortex within twenty-four hours, with the remodelling still visible a month afterwards. Dendritic spines are the tiny protrusions where neurons form connections. More spines, the reasoning went, means new circuitry — and new circuitry would explain why the change sticks.
It is an elegant story. It may also be the wrong one.
What the researchers actually did
A team led by Hannah Kramer, Meghan Hibicke and Charles Nichols at LSU Health Sciences Center designed a study to test whether those physical changes were still there when the behavioural effects were. Almost every previous experiment had looked at short time points — days, or a few weeks. Nobody had checked whether the scaffolding was still standing at the three-month mark.
They worked with Wistar Kyoto rats, an inbred strain that naturally displays despair-like behaviour, passive coping under stress, and comorbid anxiety without any experimental manipulation. These animals arrive already carrying something that resembles the phenotype under study.
Each rat received a single injection of one of three things: psilocybin, saline, or a compound called 25CN-NBOH. That third option is the clever part of the design. Psilocybin is promiscuous — it binds a range of serotonin receptors. 25CN-NBOH is selective, targeting only the 5-HT2A receptor, the one most closely associated with the psychedelic state itself. Including it let the team ask whether that single receptor is sufficient to set the long process in motion.
Then they waited. Behavioural testing came at five weeks and again at twelve.
The behaviour held
The measure was the forced swim test, in which time spent floating passively is contrasted with time spent actively swimming. Both psilocybin and 25CN-NBOH reduced immobility relative to saline — and critically, the effect size had not diminished between the five-week and twelve-week assessments. Three months after a single administration, the shift was as strong as it had been at five weeks.
The two compounds produced no obvious behavioural difference from one another, which points to something significant: activating the 5-HT2A receptor appears to be enough on its own to trigger whatever process locks the change in.
Then the brains told a different story
After the twelve-week tests, the researchers examined tissue from the medial prefrontal cortex, a region central to mood regulation and decision-making. They used high-resolution microscopy to count dendritic spines and classify their shapes, looking for exactly the structural signature that the short-term studies had reported.
It was not there.
Spine density in the treated animals was indistinguishable from controls. Gene expression for a range of presynaptic and postsynaptic markers showed no differences between groups either. Whatever architectural growth had occurred in the first days or weeks had apparently receded. By three months, the physical structure of these neurons had returned to baseline — while the behavioural effect had not budged.
This is the sort of result that quietly dismantles a consensus.
Functional plasticity: the settings, not the hardware
So the team went looking elsewhere. Using brain slice electrophysiology — inserting fine glass pipettes into individual cells to record their electrical behaviour — they examined layer 5 pyramidal neurons and sorted them into two functional types: adapting neurons, which slow their firing after an initial burst, and bursting neurons, which fire in rapid clusters.
Here the treated animals were unmistakably different.
In the psilocybin group, adapting neurons were sitting at a resting voltage closer to the threshold for firing — depolarised, primed, nearer to action. The bursting neurons showed increased excitability outright: they required less input to fire, and fired faster once they did. The 25CN-NBOH animals also showed functional changes, though not identical ones; their bursting neurons were not triggered quite as readily as those in the psilocybin group.
Three months after a single dose, with the drug long gone and the physical architecture back to normal, the cells were still running on altered settings.
That is the finding, and it is worth sitting with. The lasting effect was not written into new structure. It was written into how existing structure operates.
Why this matters beyond the laboratory
Every contemplative tradition has had to account for the same paradox that this study just stumbled into. The mystic returns from the mountain looking exactly as they did going up. The meditator who has spent thirty years on the cushion has the same body, the same history, the same set of circumstances. What has changed is not the equipment but the tuning of it — the threshold at which reaction is triggered, the ease with which a different response becomes available.
The rats, obviously, had no insight, no integration, no meaning-making. This is a study about cellular excitability in an animal model, and it would be a serious overreach to read it as evidence for anything about spiritual experience. But the shape of the finding is suggestive of something the traditions have insisted on for a very long time: that transformation is a change in disposition rather than a change in substance. The instrument was not replaced. It was retuned.
There is also a hint here about why the quality of an experience seems to matter so much in the human case. Imperial College researchers found that the depth of oceanic boundlessness during a psilocybin session predicted how much depressive symptoms improved weeks afterwards, while the merely sensory effects predicted nothing. Something about how the experience is met appears to shape what it leaves behind — which is not a claim any rat study can test, but is precisely the claim that makes the human research so difficult and so interesting.
The honest limits
This is a rat study, and rats are not people. The authors used only male animals; female responses to both stress and psychedelics can differ meaningfully, and until the work is repeated in both sexes its generality is unknown.
The forced swim test is also a contested instrument. A well-known critique argues that what it actually measures is stress-coping strategy rather than depression-like behaviour, and that treating immobility as despair oversimplifies the biology considerably. Reduced floating is a signal, not a diagnosis.
The mechanistic picture is unsettled too. Other work has complicated the receptor story: one group reported that psilocybin’s antidepressant-like and synaptic effects in mice survived blockade of the 5-HT2A receptor with ketanserin, suggesting more than one pathway may be involved, while a 2025 study argued that psilocybin’s lasting action does depend on specific pyramidal cell types and 5-HT2A receptors. The field has not converged.
The authors themselves are careful on one further point, and it deserves emphasis. Finding no structural difference at three months does not mean structural plasticity is irrelevant. The early growth of connections may function as the trigger — a temporary scaffold that sets the electrical retuning in place and is then dismantled once it has done its work. Scaffolding is not less important for being removed.
It is also worth noting, as the paper discloses, that the research was funded through sponsored agreements with two commercial parties, and that the senior author is a founder and board member of one of them. That does not invalidate the findings, but readers deserve to know it.
What remains
The study, covered in accessible detail by PsyPost, shifts the central question of psychedelic neuroscience. For years the question was whether the brain grows new connections. The better question now appears to be whether the brain learns a new way of operating — and what, exactly, holds that new operating state in place once the scaffolding comes down.
That molecular switch is still unidentified. Finding it would tell us something about far more than mushrooms.
There is an old intuition, present in almost every wisdom tradition, that a genuine awakening does not add anything to a person. It removes an obstruction, or shifts a threshold, and what was always possible becomes suddenly available. The neurons in these rats had not grown new branches. They had simply become easier to move.
This article discusses preclinical animal research and is not medical advice. Depression is a serious condition that responds to professional care, and anyone struggling with it deserves proper support from a qualified practitioner.
